Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Brian R. Hu

Urology
Faculty Physicians And Surgeons Of Llusm
26520 Cactus Ave, Suite 2021, 
Moreno Valley, CA 
Offers Telehealth
Advanced in WT1-Related Wilms Tumor Syndromes
Faculty Physicians And Surgeons Of Llusm
26520 Cactus Ave, Suite 2021, 
Moreno Valley, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Hu is an Urologist in Moreno Valley, California. Dr. Hu is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Testicular Cancer, Cystectomy, and Nephrectomy.

His clinical research consists of co-authoring 52 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in CA
Hospital Affiliations
Loma Linda University Medical Center
Arrowhead Regional Medical Center
Riverside University Health System-Medical Center
Redlands Community Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

FACULTY PHYSICIANS AND SURGEONS OF LLUSM
26520 Cactus Ave, Suite 2021, Moreno Valley, CA 92555
Other Locations
FACULTY PHYSICIANS AND SURGEONS OF LLUSM
901 San Bernardino Rd, Suite 104and302, Upland, CA 91786
FACULTY PHYSICIANS AND SURGEONS OF LLUSM
11234 Anderson St, Loma Linda, CA 92354
FACULTY PHYSICIANS AND SURGEONS OF LLUSM
26780 Barton Rd, Redlands, CA 92373
FACULTY PHYSICIANS AND SURGEONS OF LLUSM
11370 Anderson St, Loma Linda, CA 92354

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Procedure, Other
Study Phase: Not Applicable
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Enrollment Status: Withdrawn
Publish Date: April 16, 2019
Intervention Type: Other, Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

52 Total Publications

Outcomes of Prophylactic Ureteral Catheterization for Ureteral Identification During Non-Urologic Surgery.
Outcomes of Prophylactic Ureteral Catheterization for Ureteral Identification During Non-Urologic Surgery.
Journal: Journal of endourology
Published: October 31, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Hooman Djaladat
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Hooman Djaladat
Urology

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (58.5 miles away)
323-442-8444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hooman Djaladat is an Urologist in Los Angeles, California. Dr. Djaladat is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jaime Landman
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jaime Landman
Urology

Uci Department Of Urology

101 The City Dr S, 
Orange, CA 
 (40.7 miles away)
714-456-6054
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jaime Landman is an Urologist in Orange, California. Dr. Landman is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Kidney Stones, Renal Cell Carcinoma (RCC), Ureterocele, Lithotripsy, and Nephrectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Clayton S. Lau
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Clayton S. Lau
Urology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (56.6 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Clayton Lau is an Urologist in South Pasadena, California. Dr. Lau is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Bladder Cancer, Nephrectomy, and Cystectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hu's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile